Skip to content

Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021
2.45 -0.27 -9.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Recent news

  • Rating change
    BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
    Market Newswire · 2026/9/21
  • Recursion Pharmaceuticals | 8-K: Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
    SEC · 2026/11/3
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)
    TipRanks · 2026/9/16
  • Recursion Pharmaceuticals | 10-Q: Quarterly report
    SEC · 2026/11/3
  • Rating change
    Morgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)
    TipRanks · 2026/10/16
  • Rating change
    Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/10/19
  • Rating change
    Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
    TipRanks · 2026/10/16
  • Company notice
    Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake
    SEC · 2026/11/5
  • Rating change
    Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.9
    Market Newswire · 2026/10/16
  • News Flash: Analysts Just Made A Meaningful Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts
    Simply Wall St · 2026/11/5
  • Rating change
    Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
    TipRanks · 2026/9/21
  • Company notice
    Recursion Pharmaceuticals | SCHEDULE 13G/A: Others
    SEC · 2026/11/14
  • Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M Estimate
    Benzinga · 2026/11/3
  • Company notice
    Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred
    SEC · 2026/11/5
  • Rating change
    Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
    Benzinga · 2026/10/19
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
    TipRanks · 2026/10/19
  • Rating change
    BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $6
    Market Newswire · 2026/10/16
  • Company notice
    Recursion Pharmaceuticals | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6
    Market Newswire · 2026/11/4
  • Company notice
    Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Hassan Fred
    SEC · 2026/11/5
  • Rating change
    Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3
    Market Newswire · 2026/8/17
  • Company notice
    Recursion Pharmaceuticals | 424B5: Prospectus
    SEC · 2026/10/16
  • Company notice
    Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HERSHBERG ROBERT
    SEC · 2026/10/8
  • Company notice
    Recursion Pharmaceuticals | 8-K: Current report
    SEC · 2026/10/15
  • Rating change
    J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating
    Market Newswire · 2026/9/16

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.

Recursion Pharmaceuticals discussion 0 comments

Add a comment